The FDA has granted orphan status to Arcus Biosciences’ CD73 inhibitor quemliclustat for metastatic pancreatic cancer, as the ...

Arcus Biosciences' cancer drug candidate, quemliclustat, earns FDA orphan drug status, ensuring incentives and exclusivity.

Arcus Biosciences, Inc. (NYSE:RCUS), a clinical-stage, global biopharmaceutical company focused on developing differentiated molecules and combination therapies for patients with cancer, today ...

The Phase 3 study evaluating quemliclustat plus chemotherapy as a first-line treatment for metastatic pancreatic cancer is ...

Simon Arcus has resigned as the chief executive of the Wellington Chamber of Commerce and parent organisation Business ...

Arcus Biosciences announced that the Food and Drug Administration has granted its pancreatic cancer treatment, quemliclustat, with an orphan drug designation. The company said it expects its ongoing ...

A dramatic cloud formation appeared in the skies of Maryland as severe thunderstorms ripped through the state, sparking fears ...

Arcus Biosciences is a clinical-stage, global biopharmaceutical company developing differentiated molecules and combination therapies for people with cancer. In partnership with industry ...

Simon Arcus has resigned as the chief executive of the Chamber of Commerce and parent organisation Business Central, effective today.

TIGIT-targeting therapies have largely disappointed in recent months, with failed studies, terminated partnerships and ...